Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Prometheus Biosciences Inc.
Headquarters: San Diego, CA, United States of America
Website: N/A
Year Founded: 2016
Status: Acquired
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Dec 18, 2024
Product Development
Teva-Sanofi showcase best-in-class TL1A potential, without a biomarker
Duvakitug leads to clinical remission in nearly half of UC patients
BioCentury | May 29, 2024
Deals
Clinical readout spurred Merck’s $1.3B takeout of VC-backed ophthalmic play EyeBio
In milestone-heavy deal worth up to $3B total, the pharma makes a big commitment to late-stage candidate for retinal diseases
BioCentury | Mar 21, 2024
Finance
Venture report: Mirador’s $400M launch; megarounds for Clasp, Capstan, Engrail
Arch backs immunology/fibrosis start-up; JHU spinout launches with $150M; San Diego-based pair advance clinical plans in oncology and neuroscience
BioCentury | Feb 24, 2024
Product Development
Will TL1A be the gateway to precision medicine in inflammation?
Introducing precision medicine to a new disease area faces challenges beyond the biology
BioCentury | Jan 23, 2024
Data Byte
Centerview advised most of the sellers in 2023’s largest M&A deals
Centerview Partners acted as an adviser to 64% of the biotechs acquired in $1B+ deals
BioCentury | Jan 4, 2024
Deals
Parsing premiums: 2023’s biopharma M&A deals
2023’s highest-premium takeouts and its top-value deal all came early, but 4Q was notable for its pace of $1B+ deals
BioCentury | Dec 22, 2023
Discovery & Translation
Move over oncology — I&I will write the next big stories in innovation
Biotech execs, investors eye immunology and inflammation, plus neurology as innovation drivers, but precision medicine still to prove itself: a BioCentury survey
BioCentury | Nov 30, 2023
Deals
ImmunoGen’s commitment to Elahere pays off with $10.1B AbbVie takeout
Pharma sees opportunities for label expansions as it builds pipeline, gains commercial presence in solid tumors
BioCentury | Nov 7, 2023
Product Development
Is TL1A the new TNFα?
Interest is rising in autoimmune disease target TL1A. Here’s why
Items per page:
1 - 10 of 38